HEALTH TECHNOLOGY

Health Catalyst Unveils New Solution to Bring Clinical Research to Routine Healthcare

Health Catalyst | September 13, 2021

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of the Health Catalyst Research Offering for healthcare providers, biopharmaceutical companies, and clinical research organizations (CROs). The new offering will help health systems safely convert and maximize their existing clinical databases, unlocking access to mutually beneficial industry and research partnerships.

 

"For decades, clinical research has been heavily biased towards a finite number of leading urban medical centers, which tap into the same patient populations for clinical trial recruitment time and time again," said Sadiqa Mahmood, DDS, MPH, General Manager and Senior Vice President, Life Sciences Business at Health Catalyst. "Unfortunately, the vast majority of citizens don't have an opportunity to participate, and a majority of clinical studies fail to enroll on time. Our new Health Catalyst Research Offering gets to the heart of these dual issues, using research-grade data as a way to connect more patients with clinical research opportunities."

 

The new offering consists of two core components: The Health Catalyst Research Network™ and the Health Catalyst Touchstone Match™. The research network is an established cloud-based forum for collaboration, bringing together an array of hospitals, medical centers, biopharma companies, and CROs. This ecosystem is made actionable through Touchstone Match, an intelligent search function and services that support data-informed research use cases– from clinical trial feasibility analyses to searches for patients eligible for real-world studies.

 

Using existing real-world data, such as electronic health records, the new Health Catalyst Research Offering allows health systems to proactively establish relationships with CROs and sponsors, creating opportunity for revenue enhancement and improved patient outcomes.

 

For biopharma companies and CROs, the new offering represents a step towards integrating their research and clinical trials with the broader healthcare system. Key research and clinical decisions can be made with confidence using a nationally integrated data asset containing millions of records, a multi-system provider network, scalable infrastructure, and a team of data analytics experts who understand scientific process and study design.

 

"The introduction of this new solution couldn't come at a better time, as more and more sponsors and CROs shift their focus to digital or decentralized trials," said CJ Anderson, President at Cognitive Clinical Trials, a leader in community-based, embedded clinical research company for clinical trials. "The Health Catalyst Research Offering is a pivotal piece in the decentralized puzzle as it helps sponsors and CROs find new patient populations that we know fit key inclusion/exclusion criteria. This shortens that critical study start-up time so sponsors and CROs can start screening patients and meet their enrollment goals."

 

About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data-informed.

Spotlight

With the changing landscape of healthcare comes a deluge of digital data and an opportunity to use it for improvements. Analytics can help make data meaningful in many ways: providing quality-related benchmarks and targeted metrics, predicting future...


Other News
HEALTH TECHNOLOGY

Mednow Enters Into Agreement to Acquire Mednow East Inc in Ontario

Mednow Inc. | March 08, 2022

Mednow Inc. Canada’s on-demand virtual pharmacy, is pleased to announce that the Company has entered into a share purchase agreement on March 4, 2021 with Mednow East Inc.and the shareholders of Mednow East, pursuant to which the Company shall acquire all of the issued and outstanding shares of Mednow East, in consideration for an aggregate cash payment of approximately C$65,578 and the Company’s agreement to convert approximately C$1,374,422 owed by Mednow East to the Company pursuant to a pharmacy agreement dated September 15, 2020, as amended October 30, 2020 into a non-interest bearing on-demand convertible promissory note. Mednow East is an Ontario company that operates an online pharmacy, delivering prescriptions in the Province of Ontario. Mednow East has its business headquarters in Toronto and employs Mednow’s marketing and technology platform for lead generation, prescription fulfillment and customer services pursuant to the Pharmacy Agreement. Strategically, Mednow is focused on building out a national pharmacy footprint and the acquisition of Mednow East, with their presence in Ontario, helps to accelerate these goals. Prior to this acquisition, Mednow entered into the Pharmacy Agreement with Mednow East, but post-acquisition, Mednow will own 100% of a pharmacy located in Ontario, which will allow Mednow to provide free same-day pharmaceutical delivery services in the GTA and surrounding areas, and free next-day delivery in the rest of Ontario. Upon closing of the Share Purchase Agreement, Mednow East’s revenue and expenses will be consolidated with those of Mednow and the Pharmacy Agreement between the two parties will be terminated. The debt of approximately C$1,374,422 extended to Mednow East by the Company was used to fund Mednow East’s working capital and provide support for its operations. As Amir Ali Reyhany-Bozorg and Felipe Campusano are directors of the Company and Karim Nassar is the Chief Executive Officer of the Company, and each are also shareholders of Mednow East, the transaction contemplated under the Share Purchase Agreement is a related party transaction under Multilateral Instrument 61-101 –Protection of Minority Securityholders in Special Transactions. The Company is exempt from the formal valuation and minority shareholder approval requirements imposed by MI 61-101 pursuant to the exemptions in section 5.5(a) and 5.7(a) of MI 61-101, as neither the fair market value of the Shares, nor the consideration paid therefor, exceeds 25% of the Company's market capitalization. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. About Mednow Inc. Mednow is a healthcare technology company offering virtual access with a high-standard of care. Designed with accessibility and quality of care in mind, Mednow.ca provides virtual pharmacy and telemedicine services as well as doctor home visits through an interdisciplinary approach to healthcare that is focused on the patient experience. Mednow’s services include free at-home delivery of medications, a user-friendly interface for easy upload, transfer, and refill of prescriptions, access to healthcare professionals through an intuitive chat experience, a specialized PillSmart™ system that packages prescriptions and vitamins by date and time, and doctor consultations.

Read More

HEALTH TECHNOLOGY

HONEYWELL AND NARAYANA HEALTH PARTNER TO EXPLORE CO-CREATION OF HEALTHCARE TECHNOLOGIES

Honeywell | May 27, 2022

Honeywell announced the signing of a non-binding memorandum of understanding (MoU) with Narayana Hrudayalaya Limited to identify, assess and collaborate on opportunities for the latter's digital transformation journey. This will enable Narayana Health to offer technology-driven, affordable and accessible healthcare for all. The MoU is subject to definitive agreements to be executed between Honeywell and Narayana Health. "These are times of great promise and even greater opportunities in healthcare innovation. At Honeywell, we recognize this and have pivoted towards the development of technologies that will shape the future of healthcare delivery. The MoU with Narayana Health – one of India's foremost healthcare service providers – offers us an opportunity to create a strategic technology development roadmap that will eventually transform India's healthcare industry," said Suresh Venkatarayalu, Chief Technology Officer, Honeywell. "Sensors and digital technology will disrupt health care delivery. Narayana Healthcare is delighted to work with Honeywell to develop digital technologies for making health care safer, more accessible, and more affordable," said Dr. Devi Prasad Shetty, Chairman and Executive Director, Narayana Healthcare. Honeywell's Advanced Sensing Technologies (AST) healthcare business builds on the company's global leadership in sensors to offer devices and software for hospitals, clinics and elderly care facilities to improve communication, collaboration and coordination of clinical care. "The pandemic made it abundantly clear that healthcare organizations need technology that can be seamlessly integrated into existing systems and processes to streamline error prone tasks, enhance patient experience, and improve organizational agility," said Robert Robinson, Vice President and General Manager, Advanced Sensing Technologies Healthcare, Honeywell. Based on the terms of the MoU, Honeywell and Narayana Health will work towards co-innovation and introduction of new products, establish technology development centers, co-create joint capabilities in technology development and research, and undertake the development of fire safety codecs that ensure an end-to-end life safety system to make hospitals safer. As a technology partner, Honeywell will also help enhance and optimize Narayana Health's digital processes and offer training to its employees. The healthcare industry is continuously evolving to keep up with increasing regulatory pressures, while maintaining an environment where patients and staff feel safe. COVID-19 highlighted the need for bringing efficiencies in healthcare delivery to enable fewer personnel to do more onsite. The growth in telemedicine also opened newer avenues for hospitals to manage patient care. Healthcare providers often struggle with developing the right approach to stay ahead of these changes. To help meet some of these challenges, last year Honeywell launched its Real-Time Health Monitoring System (RTHMS). This is a smart edge-to-cloud communication platform for remote and real-time patient monitoring that acts as a bridge between caregiver and patient. This offering integrates hardware and software to improve care delivery, enhance healthcare worker productivity, and enable process efficiency. By digitizing and automating critical tasks, RTHMS can reduce hospital administrative tasks by 35%.1 "Narayana Healthcare has made remarkable progress in using technology to improve clinical outcomes and increase healthcare delivery efficiency. Honeywell's sensor-based applications will complement our efforts in real-time patient monitoring and fire safety, raising the bar for others to meet," Dr. Emmanuel Rupert, Managing Director and Group Chief Executive Officer, Narayana Hrudayalaya Limited Honeywell has a robust portfolio of healthcare technologies – from a patient's first visit, to diagnosis, and returning home from care, Honeywell has the technologies to help healthcare providers increase productivity, efficiency, and shape the future of their organizations. About Honeywell Honeywell is a Fortune 100 technology company that delivers industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom.

Read More

FUTURE OF HEALTHCARE

Trillium Community Health Plan Successfully Resolves Corrective Action Plan with OHA

Trillium Community Health Plan | June 03, 2022

Trillium Community Health Plan is pleased to announce it has successfully closed the Tri-County Expansion Corrective Action Plan (CAP) with Oregon Health Authority effective June 1, 2022. As a result of this process, Trillium has implemented many practices that have further strengthened the plan's ability to coordinate high-quality healthcare and services, with a special focus on increasing access to care and addressing social determinants of health for Oregon Health Plan members in Clackamas, Multnomah, and Washington counties. In September 2020, OHA issued a CAP for Trillium's Medicaid plan as a condition of expansion into the Tri-County service area. OHA asked Trillium to focus on specific improvements to its network, health equity and language access, community engagement, and intensive care coordination. Leveraging the extensive expertise of its many work groups, committees, and community partnerships, including the Network Adequacy Collaborative and Health Equity Strategy Committee, and with contributions from tribal liaisons, traditional health worker liaisons, and the development of the Community Advisory Council, Trillium has addressed and resolved all CAP requirements. Today, Trillium serves more than 28,000 members in the Tri-County area. Through the CAP, the health plan made several improvements to enhance access to care and services for all members, including The creation of a fully compliant and engaged Community Advisory Council, made up largely of Trillium members representing diverse demographics and lived experience; New partnerships with the regional health equity coalition, tribal organizations, and community-based groups, which further support Trillium members with access to culturally sensitive healthcare, food insecurity, and other investments A robust behavioral health provider network to meet the needs of members; The Network Adequacy Collaborative to ensure all network related issues, including health equity, are identified and addressed promptly; and, A renewed internal committee structure to align plan efforts and center equity on strategic planning. "Trillium is committed to providing equitable, culturally sensitive, integrated care for all of our members in Oregon. We want to thank OHA for their continued partnership throughout this process, which has allowed us to enhance our systems, processes, and partnerships, improving our ability to identify local needs, remove barriers to care, develop service innovations, and collaborate across organizations to enact lasting change within our communities." Justin Lyman, Interim President and CEO of Trillium Trillium extends its appreciation to OHA for its partnership throughout this process. About Trillium Community Health Plan Trillium Community Health Plan serves Oregon Health Plan members through the CCO model, which began in 2012. Trillium is a recognized leader for outstanding coordination of care. It was first awarded a contract with the state of Oregon to help manage care for the Oregon Health Plan in 1999. Trillium partners with an extensive group of providers to improve care and access to services for OHP members.

Read More

FUTURE OF HEALTHCARE

Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study

Virta Health | June 07, 2022

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health. These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt. For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta’s treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent. The outcomes of Jane Ann and Virta’s other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission. One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly. These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta’s approach to impact a wide range of conditions amid America’s metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events, and diabetes-related deaths during the COVID-19 pandemic. Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% of patients were retained at one year. In contrast, in Virta’s trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear. “Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I’ve learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before.” Additional key outcomes demonstrating the success of Virta’s approach at five years include Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications. Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%. Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%. Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease. “Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care. The patient outcomes set a new standard for real-world applications of diabetes treatment." Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH Diabetes Prevention Program lifestyle intervention. The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future. Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, “My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta’s lifestyle changed my lifestyle!” About Virta Health Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes.

Read More

Spotlight

With the changing landscape of healthcare comes a deluge of digital data and an opportunity to use it for improvements. Analytics can help make data meaningful in many ways: providing quality-related benchmarks and targeted metrics, predicting future...

Resources